Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec.
Sanofi will licence its infectious disease research and early-stage development portfolio and transfer its infectious disease research unit, which includes more than 100 employees to Evotec. Sanofi will pay Evotec an initial one-time cash upfront payment of € 60 m and provide further significant long-term funding to ensure support and progression of the portfolio. Sanofi will retain certain option rights on the development, manufacturing, and commercialisation of anti-infective products.
This transaction is expected to close in the first half of 2018, subject to finalisation of definitive agreements and completion of the appropriate social process.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, firstname.lastname@example.org